혈관 그라프트 시장 보고서 : 제품별, 원재료별, 용도별, 최종 사용자별, 지역별(2026-2034년)

The global vascular grafts market size reached USD 2.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.20% during 2026-2034. The increasing number of fatal road accidents and trauma cases, rising inclination towards medical tourism, and the growing number of surgical procedures, especially among the geriatric population, are some of the major factors propelling the market.

Vascular grafts are medical devices used to replace, bypass, or restore functionality to damaged or diseased blood vessels in the human body. They serve as artificial conduits that facilitate blood flow and ensure that vital organs and tissues receive adequate blood supply. They can be made from various materials, including synthetic polymers like dacron and teflon or biological materials like vein segments harvested from the patient or a donor. They are commonly used in surgical procedures, such as coronary artery bypass grafting (CABG), peripheral artery bypass, and hemodialysis access.

The increasing number of fatal road accidents and the expanding number of trauma cases are driving the demand for vascular grafts around the world. Moreover, the rising inclination towards medical tourism, wherein people are traveling to countries with advanced healthcare systems for specialized treatments, including vascular graft surgeries, is favoring the growth of the market. In addition, the growing number of surgical procedures and the rising global geriatric population, which is more susceptible to medical disorders, are influencing the market positively.

Apart from this, the increasing focus on preventive healthcare, which leads to early diagnosis and treatment of vascular conditions, is catalyzing the need for vascular grafts as a preemptive measure. Furthermore, the growing number of ambulatory surgical centers, which offer quicker and more convenient surgical procedures, are creating a positive outlook for the market.

Vascular Grafts Market Trends/Drivers:

Increase in prevalence of lifestyle diseases

One of the primary factors that are driving the demand for vascular grafts is the surging prevalence of lifestyle-related diseases like obesity and diabetes. These conditions significantly elevate the risk of developing vascular problems that may necessitate graft surgeries. As lifestyle diseases continue to surge, the requirement for vascular grafts to manage associated vascular complications is likely to grow substantially.

Rise in public awareness and education

Increasing public awareness about vascular diseases and the available treatment options is also catalyzing thee demand for vascular grafts. Public health campaigns, educational programs, and digital platforms are educating people about the risks of vascular conditions and the importance of early diagnosis and treatment. This heightened awareness is leading to more people seeking medical advice and, consequently, increasing the number of vascular graft surgeries being performed.

Growing regulatory approvals and reimbursement policies

Favorable regulatory approvals and reimbursement policies play a crucial role in driving the market for vascular grafts. Regulatory bodies of numerous countries have stringent but clear pathways for the approval of new medical devices, including vascular grafts. Once approved, these products are more readily adopted by medical facilities. Additionally, comprehensive reimbursement policies make it financially feasible for patients to opt for these advanced treatments, further elevating the demand for vascular grafts in the market.

Vascular Grafts Industry Segmentation:

The research provides an analysis of the key trends in each segment of the global vascular grafts market report, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on product, raw material, application, and end user.

Breakup by Product:

• Endovascular Stent Grafts
• Hemodialysis Access Grafts
• Coronary Artery By-Pass Grafts
• Vascular Grafts for Aorta Disease
• Peripheral Vascular Graft.

Endovascular stent grafts dominate the market

Hemodialysis access grafts serve a different purpose but are equally important in the field of medicine. They are used to provide reliable and durable vascular access for patients who require long-term hemodialysis, a treatment for kidney failure. Typically made of synthetic materials like PTFE (polytetrafluoroethylene), these grafts are surgically implanted to connect an artery to a vein, usually in the arm. Hemodialysis access grafts offer the advantage of immediate use, as opposed to AV fistulas that often require weeks to mature before they can be used for dialysis.

Breakup by Raw Material:

• Polytetrafluoroethylene (PTFE)
• Polyester
• Polyurethane
• Biosyntheti.

Polytetrafluoroethylene (PTFE) holds the largest share in the market

Polyester is another widely used synthetic material in the construction of vascular grafts, particularly in applications like aortic and peripheral vascular bypass surgeries. Often sold under the brand name Dacron, polyester vascular grafts have been used for several decades and have a well-established safety and efficacy profile. Polyester is known for its excellent mechanical properties, including tensile strength and durability, which makes it a preferred choice for long-term implantation. It also possesses good biocompatibility and allows for tissue ingrowth, which helps in anchoring the graft securely in place over time.

Breakup by Application:

• Cardiac Aneurysm
• Kidney Failure
• Vascular Occlusion
• Coronary Artery Diseas.

Cardiac aneurysm dominates the market

The use of vascular grafts in this context aims to bypass or replace the weakened section of the blood vessel or heart wall, thus preventing rupture and subsequent life-threatening events. In surgeries, such as coronary artery bypass grafting (CABG), graft materials like polyester or PTFE can be used to reroute blood flow around blocked or compromised arteries, thus restoring adequate blood supply to heart muscles.

In the context of kidney failure, vascular grafts are commonly used to create a functional access point for hemodialysis. When a kidney fails of a patient to adequately filter blood, hemodialysis becomes necessary to remove waste products. Reliable vascular access is crucial for this process. Hemodialysis access grafts, often made from PTFE, are used to surgically connect an artery to a vein, usually in the arm. This connection, known as an arteriovenous (AV) graft, provides a high-flow circuit that facilitates efficient blood removal and return during dialysis sessions. These grafts are particularly useful for patients who cannot use an arteriovenous fistula, either due to poor vein quality or other medical considerations.

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers (ASCs.)

Hospitals hold the largest share in the market

Hospitals often have the comprehensive medical infrastructure, including specialized surgical units, advanced diagnostic equipment, and postoperative care facilities, that allow for the successful implantation and maintenance of these grafts. Given the complexity of many vascular surgeries and the need for specialized medical personnel, such as cardiovascular surgeons and interventional radiologists, hospitals are well-suited to be major end users of vascular grafts.

Ambulatory surgical centers (ASCs) also serve as significant end users of vascular grafts, although their scope may be more limited as compared to hospitals. ASCs are healthcare facilities wherein surgeries that do not require an overnight hospital stay are performed. Due to advancements in minimally invasive surgical (MIS) techniques, certain procedures involving vascular grafts, such as some types of endovascular stent placements, can now be conducted in these settings. ASCs offer the advantage of quicker patient turnover, lower cost, and a more streamlined patient experience.

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Afric.

North America exhibits a clear dominance, accounting for the largest vascular grafts market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The surging prevalence of diabetes among the masses represents one of the primary factors bolstering the market growth in the North American region. Moreover, the rising adoption of cutting-edge diagnostic technologies like AI and advanced imaging is contributing to the market growth in the region. Besides this, the growing preference for MI surgeries is influencing the market positively.

Competitive Landscape:

The leading companies are developing bioengineered and drug-eluting grafts that aim to mitigate these drawbacks by incorporating living cells or biological molecules to improve biocompatibility and encourage tissue integration. They are also coated with pharmaceutical agents that are slowly released into the bloodstream, which reduces the risk of clot formation and vessel narrowing post-surgery.

Moreover, key players are adopting the use of 3D printing technologies to create custom vascular grafts that match the specific anatomical needs of individual patients and reduce the risk of complications that can arise from ill-fitting grafts. They are also utilizing nanotechnology to offer unique mechanical and biological properties, which include better flexibility and reduced thrombogenicity.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• B. Braun SE (B. Braun Holding GmbH & Co. KG)
• Becton, Dickinson and Company
• Cook Group Incorporated
• Cordis
• CryoLife Inc.
• Getinge AB
• Heat Medical Europe BV
• LeMaitre Vascular
• Medtronic plc
• Terumo Corporation
• W. L. Gore & Associates Inc.

Key Questions Answered in This Report

• How big is the global vascular grafts market?
• What is the expected growth rate of the global vascular grafts market during 2026-2034?
• What are the key factors driving the global vascular grafts market?
• What has been the impact of COVID-19 on the global vascular grafts market?
• What is the breakup of the global vascular grafts market based on the product?
• What is the breakup of the global vascular grafts market based on the raw material?
• What is the breakup of the global vascular grafts market based on the application?
• What is the breakup of the global vascular grafts market based on the end user?
• What are the key regions in the global vascular grafts market?
• Who are the key players/companies in the global vascular grafts market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Vascular Grafts Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Endovascular Stent Grafts
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Hemodialysis Access Grafts
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Coronary Artery By-Pass Grafts
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Vascular Grafts for Aorta Disease
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Peripheral Vascular Grafts
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Raw Material

• 7.1 Polytetrafluoroethylene (PTFE)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Polyester
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Polyurethane
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Biosynthetic
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Application

• 8.1 Cardiac Aneurysm
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Kidney Failure
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Vascular Occlusion
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Coronary Artery Disease
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Ambulatory Surgical Centers (ASCs)
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 B. Braun SE (B. Braun Holding GmbH & Co. KG)
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Becton, Dickinson and Company
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Cook Group Incorporated
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Cordis
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 CryoLife Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Getinge AB
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Heat Medical Europe BV
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 LeMaitre Vascular
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Medtronic plc
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 Terumo Corporation
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
  • 15.3.12 W. L. Gore & Associates Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio